Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age a… Read more
Vertex Pharmaceuticals Inc - Asset Resilience Ratio
Vertex Pharmaceuticals Inc (VRTX) has an Asset Resilience Ratio of 25.77% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Vertex Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Vertex Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.61 Billion | 25.77% |
| Total Liquid Assets | $6.61 Billion | 25.77% |
Asset Resilience Insights
- Very High Liquidity: Vertex Pharmaceuticals Inc maintains exceptional liquid asset reserves at 25.77% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vertex Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Vertex Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Vertex Pharmaceuticals Inc (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Vertex Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.77% | $6.61 Billion | $25.64 Billion | +18.91pp |
| 2024-12-31 | 6.86% | $1.55 Billion | $22.53 Billion | +3.13pp |
| 2023-12-31 | 3.74% | $849.20 Million | $22.73 Billion | +2.22pp |
| 2022-12-31 | 1.51% | $274.50 Million | $18.15 Billion | -3.92pp |
| 2021-12-31 | 5.43% | $729.90 Million | $13.43 Billion | -0.27pp |
| 2020-12-31 | 5.71% | $670.70 Million | $11.75 Billion | -2.70pp |
| 2019-12-31 | 8.40% | $698.97 Million | $8.32 Billion | +0.11pp |
| 2018-12-31 | 8.30% | $518.11 Million | $6.25 Billion | -3.64pp |
| 2017-12-31 | 11.94% | $423.25 Million | $3.55 Billion | +3.28pp |
| 2016-12-31 | 8.66% | $250.61 Million | $2.89 Billion | -4.46pp |
| 2015-12-31 | 13.12% | $327.69 Million | $2.50 Billion | -19.49pp |
| 2014-12-31 | 32.61% | $761.85 Million | $2.34 Billion | -6.02pp |
| 2013-12-31 | 38.63% | $895.78 Million | $2.32 Billion | +8.48pp |
| 2012-12-31 | 30.15% | $831.81 Million | $2.76 Billion | +7.75pp |
| 2011-12-31 | 22.39% | $493.60 Million | $2.20 Billion | -23.29pp |
| 2010-12-31 | 45.68% | $788.21 Million | $1.73 Billion | +2.82pp |
| 2009-12-31 | 42.87% | $838.25 Million | $1.96 Billion | -2.31pp |
| 2008-12-31 | 45.18% | $442.99 Million | $980.48 Million | +27.69pp |
| 2007-12-31 | 17.49% | $105.21 Million | $601.48 Million | -35.84pp |
| 2006-12-31 | 53.33% | $491.45 Million | $921.58 Million | +1.76pp |
| 2005-12-31 | 51.57% | $283.11 Million | $549.00 Million | -10.27pp |
| 2004-12-31 | 61.84% | $337.31 Million | $545.45 Million | -5.11pp |
| 2003-12-31 | 66.95% | $485.00 Million | $724.41 Million | +2.36pp |
| 2002-12-31 | 64.59% | $526.89 Million | $815.72 Million | +4.71pp |
| 2001-12-31 | 59.88% | $554.00 Million | $925.13 Million | +51.28pp |
| 2000-12-31 | 8.61% | $66.51 Million | $772.88 Million | -- |